**************Psychedelic Biotech Surge**************
Key Questions
What triggered the recent surge in psychedelic biotech stocks?
A fresh Trump Executive Order fast-tracking FDA reviews and allocating $50M for PTSD funding drove gains, with CMPS up 50%/+24.5%, ATAI +33%/+28%, GHRS +30%/+17%, and Definium +13%. RBC analysts noted this could accelerate the commercialization path for psychedelics.
How has Aura Biosciences (AURA) performed relative to the medical sector?
AURA is up 36.5% YTD, outperforming the broader medical sector. It holds a Zacks #2 Buy rating, making it a standout for investors seeking top performers in medical stocks.
What other healthcare stocks are benefiting from the current rotation?
BDSX saw a +89% volume explosion, reinforcing rotation into ZNTL, BFRG, and MESO amid the Russell 2000 (RUT) rally. This movement supports short-line trading opportunities driven by regulatory easing.
CMPS +50%/+24.5%, ATAI +33%/+28%, GHRS +30%/+17%, Definium +13% on fresh Trump EO fast-tracking FDA reviews/$50M PTSD funding; AURA +36.5% YTD outperf medical sector Zacks #2 Buy/BDSX +89% vol explosion reinforces ZNTL/BFRG/MESO healthcare rotation amid RUT rally for short-line flips/reg easing.